Table 2 Patients' features
c.35 G>A KRASmutant | Other KRASmutant | KRASwild-type | |
|---|---|---|---|
Total Number (%) | Total Number (%) | Total Number (%) | |
Number of patients | 15 (25) | 13 (22) | 31 (53) |
Sex | |||
male/female | 11/4 | 5/8 | 21/10 |
Age, years | |||
median | 67 | 63 | 64 |
range | 51 to 73 | 48 to 71 | 42 to 73 |
≥65 years | 8 (53) | 5 (38) | 13 (42) |
WHO Performance Status | |||
0 | 13 (87) | 13 (100) | 28 (90) |
1-2 | 2 (13) | - | 3 (10) |
Metastatic disease | |||
metachronous | 5 (33) | 2 (15) | 10 (32) |
synchronous | 10 (67) | 11 (85) | 21 (68) |
Primary tumor | |||
colon | 10 (67) | 10 (77) | 14 (45) |
rectum | 5 (33) | 3 (23) | 17 (55) |
Sites of metastases | |||
liver | 12 (80) | 8 (61.5) | 19 (61) |
lung | 3 (20) | 2 (15) | 7 (23) |
lymph nodes | 4 (27) | 4 (31) | 10 (32) |
local | 2 (13) | 1 (8) | 6 (19) |
other | 4 (27) | 2 (15) | 2 (6) |
Number of involved sites | |||
1 | 8 (53) | 9 (69) | 17 (55) |
≥2 | 7 (47) | 4 (31) | 14 (45) |
Single metastatic sites | |||
liver-limited | 6 (40) | 7 (54) | 12 (39) |
other than liver | 2 (13) | 2 (15) | 7 (22) |
lung | 1 (6.5) | 1 (8) | 2 (6) |
lymph nodes | - | 1 (8) | 2 (6) |
Local | 1 (6.5) | - | 3 (10) |
multiple metastatic site | 7 (47) | 4 (31) | 12 (39) |
Liver metastases | |||
single | 2 (13) | 1 (8) | 8 (26) |
multiple | 10 (67) | 7 (54) | 11 (35) |
Previous adjuvant chemotherapy: | 1 (6.5) | 1 (8) | 6 (19) |
FA/5-FU bolus | - | - | 3 (10) |
Capecitabine | - | - | - |
FOLFOX4 | 1 (6.5) | 1 (8) | 2 (6) |
XelOx | - | - | 1 (3) |
Previous radiotherapy: | 1 (6.5) | - | 4 (13) |
RT alone | - | - | - |
RT+CT (5-FU c.i.) | - | - | 2 (6) |
RT+CT (XELOX) | 1 (6.5) | - | 2 (6) |